ENLV Enlivex Ltd.
$0.96▼ -2.16%
Healthcare
Other
After hours
$0.95▼ -0.98%
Sep 11, 7:31 PM ET
Volume 242.3K
Avg Volume (10D) 332.0K
Key Metrics & Fundamentals
Market Cap
$16.78M
P/E Ratio
0.0
Div Yield
–%
52W Range
0.95 - 27.15
% vs 50 MA
-68.58%
% vs 200 MA
-91.27%
RSI-14
14.6
MACD Histogram
+0.1100
Beta (1Y vs SPY)
1.27
Free Cash Flow
-$2.63M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.64B
COGS
–
Operating Exp
$5.86M
Operating Income
-$5.86M
EBIT
-$5.86M
Pretax Income
$1.63B
Net Income
$1.24B
Price & Volume History
Loading chart…
Recent News
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks · Sep 1, 2026 1:55 PM
Enlivex Shares Plunge After $400 Million Private Placement Deal
MT Newswires · Jul 28, 2026 7:03 PM
Top Midday Decliners
MT Newswires · Jul 28, 2026 6:49 PM
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
Zacks · Jul 13, 2026 4:00 PM
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Jul 13, 2026 1:35 PM
Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis
MT Newswires · Jul 13, 2026 12:33 PM
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
Investing.com · Jul 13, 2026 11:30 AM
Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis
MT Newswires · Jun 15, 2026 1:38 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ENLV's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.